Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Genomma Lab InternacionalB de CV paidMXN27 Mil more to buy back shares than it received from issuing new shares.
It receivedMXN495 Mil from issuing more debt.
It paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentMXN195 Mil paying cash dividends to shareholders.
It spentMXN171 Mil on other financial activities.
In all, Genomma Lab InternacionalB de CVearnedMXN102 Mil on financial activities for the
three
months ended in Mar. 2026.
Genomma Lab InternacionalB de CV (MEX:LABB) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Genomma Lab InternacionalB de CV's issuance of stock for the
three
months ended in Mar. 2026 was MXN0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Genomma Lab InternacionalB de CV's repurchase of stock for the
three
months ended in Mar. 2026 was MXN-27 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Genomma Lab InternacionalB de CV's net issuance of debt for the
three
months ended in Mar. 2026 was MXN495 Mil.
Genomma Lab InternacionalB de CV receivedMXN495 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Genomma Lab InternacionalB de CV's net issuance of preferred for the
three
months ended in Mar. 2026 was MXN0 Mil.
Genomma Lab InternacionalB de CV paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Genomma Lab InternacionalB de CV's cash flow for dividends for the
three
months ended in Mar. 2026 was MXN-195 Mil.
Genomma Lab InternacionalB de CV spentMXN195 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Genomma Lab InternacionalB de CV's other financing for the
three
months ended in Mar. 2026 was MXN-171 Mil.
Genomma Lab InternacionalB de CV spentMXN171 Mil on other financial activities.
Genomma Lab InternacionalB de CV Cash Flow from Financing Related Terms
Genomma Lab InternacionalB de CV Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Cash Flow from Financing Chart
Genomma Lab InternacionalB de CV Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-419 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN-419 Mil mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Cash Flow from Financing of MXN-419 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Cash Flow from Financing too high?
Genomma Lab InternacionalB de CV's current Cash Flow from Financing is MXN-419 Mil. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Cash Flow from Financing compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Cash Flow from Financing of MXN-419 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Cash Flow from Financing is MXN-419 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN14.97 — trading 15.1% below its estimated fair value. The current Cash Flow from Financing is MXN-419 Mil. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Cash Flow from Financing is MXN-419 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.97 is trading 15.1% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Cash Flow from Financing: MXN-419 Mil
GF Value™: MXN17.64 vs. price of MXN14.97 (15.1% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
